168766-15-2Relevant articles and documents
Diphenyl-aminopyrimidine compound for inhibiting kinase activity
-
Paragraph 0216; 0217; 0218; 0219; 0224; 0225, (2019/05/04)
The invention relates to a diphenyl-aminopyrimidine compound with an inhibiting function on protein tyrosine kinase, a pharmaceutical composition containing the diphenyl-aminopyrimidine compound, andpreparation and application of the diphenyl-aminopyrimidine compound, in particular to a compound shown as the formula (I) and pharmaceutically acceptable salt or crystal forms or prodrugs or metabolin or aquo-complex or solvate or isotope derivatives thereof, wherein R1, R2, R5, R6, R7, R8 and W are defined as the description. The compound can be used for treating ALK-mediated cancer related symptoms, such as non-small cell lung cancer or breast cancer or neural tumors or esophagus cancer or soft tissue cancer or lymphoma or leukemia. The formula is shown in the specification.
Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors
Choi, Seoung-Ryoung,Pradhan, Anupam,Hammond, Nicholas L.,Chittiboyina, Amar G.,Tekwani, Babu L.,Avery, Mitchell A.
, p. 3841 - 3850 (2008/02/11)
Plasmodium falciparum lactate dehydrogenase (pfLDH) is a key enzyme for energy generation of malarial parasites and is a potential antimalarial chemotherapeutic target. It is known that the oxamate moiety, a pyruvate analog, alone shows higher inhibition